BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21509910)

  • 1. Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis.
    van Schaik FD; Oldenburg B; Offerhaus GJ; Schipper ME; Vleggaar FP; Siersema PD; van Oijen MG; Ten Kate FJ
    Inflamm Bowel Dis; 2012 Mar; 18(3):480-8. PubMed ID: 21509910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemistry in the diagnosis of dysplasia in chronic inflammatory bowel disease colorectal polyps.
    B Brahim E; Mrabet A; Jouini R; Koubaa W; B Sidhom R; Elloumi H; Chadli A
    Arab J Gastroenterol; 2016 Sep; 17(3):121-126. PubMed ID: 27567189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
    Dorer R; Odze RD
    Am J Surg Pathol; 2006 Jul; 30(7):871-7. PubMed ID: 16819330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance.
    Navaneethan U; Jegadeesan R; Gutierrez NG; Venkatesh PG; Hammel JP; Shen B; Kiran RP
    J Crohns Colitis; 2013 Dec; 7(12):e684-91. PubMed ID: 23916526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Misclassification of dysplasia in patients with inflammatory bowel disease: consequences for progression rates to advanced neoplasia.
    van Schaik FD; ten Kate FJ; Offerhaus GJ; Schipper ME; Vleggaar FP; van der Woude CJ; Stokkers PC; de Jong DJ; Hommes DW; van Bodegraven AA; Siersema PD; Oldenburg B;
    Inflamm Bowel Dis; 2011 May; 17(5):1108-16. PubMed ID: 20824815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of ATF6 as a marker of pre-cancerous atypical change in ulcerative colitis-associated colorectal cancer: a potential role in the management of dysplasia.
    Hanaoka M; Ishikawa T; Ishiguro M; Tokura M; Yamauchi S; Kikuchi A; Uetake H; Yasuno M; Kawano T
    J Gastroenterol; 2018 May; 53(5):631-641. PubMed ID: 28884228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis.
    Pekow JR; Hetzel JT; Rothe JA; Hanauer SB; Turner JR; Hart J; Noffsinger A; Huo D; Rubin DT
    Inflamm Bowel Dis; 2010 Aug; 16(8):1352-6. PubMed ID: 20027656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin D1 and p21 in ulcerative colitis-related inflammation and epithelial neoplasia: a study of aberrant expression and underlying mechanisms.
    Wong NA; Mayer NJ; Anderson CE; McKenzie HC; Morris RG; Diebold J; Mayr D; Brock IW; Royds JA; Gilmour HM; Harrison DJ
    Hum Pathol; 2003 Jun; 34(6):580-8. PubMed ID: 12827612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical analysis of chromogranin A and p53 expressions in ulcerative colitis-associated neoplasia: neuroendocrine differentiation as an early event in the colitis-neoplasia sequence.
    Shigaki K; Mitomi H; Fujimori T; Ichikawa K; Tomita S; Imura J; Fujii S; Itabashi M; Kameoka S; Sahara R; Takenoshita S
    Hum Pathol; 2013 Nov; 44(11):2393-9. PubMed ID: 24029705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history of low grade dysplasia in patients with primary sclerosing cholangitis and ulcerative colitis.
    Venkatesh PG; Jegadeesan R; Gutierrez NG; Sanaka MR; Navaneethan U
    J Crohns Colitis; 2013 Dec; 7(12):968-73. PubMed ID: 23433613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 immunohistochemistry of ulcerative colitis-associated with dysplasia and carcinoma.
    Sato A; MacHinami R
    Pathol Int; 1999 Oct; 49(10):858-68. PubMed ID: 10571818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metallothionein: early marker in the carcinogenesis of ulcerative colitis-associated colorectal carcinoma.
    Bruewer M; Schmid KW; Krieglstein CF; Senninger N; Schuermann G
    World J Surg; 2002 Jun; 26(6):726-31. PubMed ID: 12053227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p16, cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus.
    Shi XY; Bhagwandeen B; Leong AS
    Appl Immunohistochem Mol Morphol; 2008 Oct; 16(5):447-52. PubMed ID: 18665038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation.
    Risques RA; Lai LA; Himmetoglu C; Ebaee A; Li L; Feng Z; Bronner MP; Al-Lahham B; Kowdley KV; Lindor KD; Rabinovitch PS; Brentnall TA
    Cancer Res; 2011 Mar; 71(5):1669-79. PubMed ID: 21363920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The sharp decline of beta estrogen receptors expression in long-lasting ulcerative-associated carcinoma.
    Principi M; Scavo MP; Piscitelli D; Villanacci V; Lovero R; Losurdo G; Girardi B; Ierardi E; Di Leo A
    Scand J Gastroenterol; 2015 Aug; 50(8):1002-10. PubMed ID: 25862314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2 and Ki-67 immunohistochemical markers in the assessment of long-standing ulcerative colitis associated dysplasia.
    Frăţilă OC; Iliaş TI
    Rom J Morphol Embryol; 2013; 54(1):143-9. PubMed ID: 23529322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pattern of CD44 and matrix metalloproteinase 9 expression is a useful predictor of ulcerative colitis-associated dysplasia and neoplasia.
    AbdElazeem MA; El-Sayed M
    Ann Diagn Pathol; 2015 Dec; 19(6):369-74. PubMed ID: 26420348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fate of indefinite and low-grade dysplasia in ulcerative colitis and primary sclerosing cholangitis colitis before and after liver transplantation.
    Eaton JE; Smyrk TC; Imam M; Pardi DS; Loftus EV; Owens VL; Talwalkar JA
    Aliment Pharmacol Ther; 2013 Oct; 38(8):977-87. PubMed ID: 24033551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis.
    Li Y; de Haar C; Chen M; Deuring J; Gerrits MM; Smits R; Xia B; Kuipers EJ; van der Woude CJ
    Gut; 2010 Feb; 59(2):227-35. PubMed ID: 19926618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.